Promising drug cocktail before and after transplant shows potential in myeloma

NCT ID NCT01816971

First seen Apr 25, 2026 · Last updated Apr 28, 2026 · Updated 1 time

Summary

This study tested a combination of three drugs (carfilzomib, lenalidomide, and dexamethasone) given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see if this approach could kill more cancer cells and improve response rates. While the treatment aims to control the disease, patients may need ongoing therapy to manage their condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE I MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber

    Boston, Massachusetts, 02215, United States

  • Princess Margaret

    Toronto, Ontario, M5T 2M9, Canada

  • Sarah Cannon Cancer Center

    Nashville, Tennessee, 37203, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637-1470, United States

  • Washington University in St Louis

    St Louis, Missouri, 63130, United States

Conditions

Explore the condition pages connected to this study.